Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

Investigational Site Number: 0560001, Leuven, Belgium

Investigational Site Number: 2500001, Bron, France

Investigational Site Number: 2500003, Paris, France

Investigational Site Number: 2500002, Paris, France

Investigational Site Number: 3800001, Ancona, Italy

Investigational Site Number: 3800003, Palermo, Italy

Investigational Site Number: 7240001, Madrid, Spain

Investigational Site Number: 7240002, Madrid, Spain

Investigational Site Number: 7240003, Zaragoza, Spain

Investigational Site Number: 8260001, Birmingham, United Kingdom

Investigational Site Number: 8260002, London, United Kingdom